Oral Vaccination Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Syrian Hamster Challenge Model.
J Infect Dis
; 225(1): 34-41, 2022 01 05.
Article
in English
| MEDLINE | ID: covidwho-1605626
ABSTRACT
BACKGROUND:
Vaccines that are shelf stable and easy to administer are crucial to improve vaccine access and reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission around the world.METHODS:
In this study, we demonstrate that an oral, adenovirus-based vaccine candidate protects against SARS-CoV-2 in a Syrian hamster challenge model.RESULTS:
Hamsters administered 2 doses of VXA-CoV2-1 showed a reduction in weight loss and lung pathology and had completely eliminated infectious virus 5 days postchallenge. Oral immunization induced antispike immunoglobulin G, and neutralizing antibodies were induced upon oral immunization with the sera, demonstrating neutralizing activity.CONCLUSIONS:
Overall, these data demonstrate the ability of oral vaccine candidate VXA-CoV2-1 to provide protection against SARS-CoV-2 disease.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Mesocricetus
/
Adenovirus Vaccines
/
COVID-19 Vaccines
/
COVID-19
Topics:
Vaccines
Limits:
Animals
Language:
English
Journal:
J Infect Dis
Year:
2022
Document Type:
Article
Affiliation country:
Infdis
Similar
MEDLINE
...
LILACS
LIS